From the Research
Gefitinib is not mentioned in the provided evidence, however, based on the available information, the survival rate with Gilteritinib treatment, which is a similar tyrosine kinase inhibitor, is around 9.3 months in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia 1. The provided evidence discusses the efficacy and safety of Gilteritinib in the treatment of relapsed or refractory FLT3-mutated acute myeloid leukemia.
- The study published in the New England Journal of Medicine in 2019 found that Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML 1.
- The median overall survival in the Gilteritinib group was 9.3 months, compared to 5.6 months in the chemotherapy group.
- The study also found that Gilteritinib was generally well tolerated, with the most common adverse events of grade 3 or higher being febrile neutropenia, anemia, and thrombocytopenia. It's worth noting that the evidence provided does not directly answer the question about Gefitinib, but rather discusses Gilteritinib, which is a different medication.
- However, based on the available information, it can be inferred that tyrosine kinase inhibitors like Gilteritinib may have a positive effect on survival rates in certain patient populations.
- To determine the survival rate with Gefitinib treatment, further research and evidence would be needed.